John Libbey Eurotext

Médecine thérapeutique / Médecine de la reproduction, gynécologie et endocrinologie

Premature ovarian failure secondary to chemotherapy: what molecules? what mechanisms? Volume 19, issue 1, Janvier-Février-Mars 2017

Figures

  • Figure 1

Tables

Authors
1 Service de gynécologie endocrinienne et médecine de la reproduction – hôpital Jeanne de Flandre – CHRU de Lille, avenue Eugène Avinée,
59037 Lille cedex
2 Service de gynécologie médicale,
orthogénie et médecine du couple,
hôpital Jeanne de Flandre,
CHRU de Lille,
avenue Eugène Avinée,
59037 Lille cedex
3 EA 4308,
gamétogenèse et qualité du gamète,
université Lille 2,
Lille
* Tirés à part
  • Key words: premature ovarian failure, chemotherapy, alkylating agents, ovarian reserve, cancer
  • DOI : 10.1684/mte.2017.0648
  • Page(s) : 29-38
  • Published in: 2017

Female fertility preservation has become a true medical issue in the management of cancers in women of childbearing age. The knowledge of the risk of ovarian failure is essential to optimize the support of concerned women. The objective of this review is to propose a synthesis on risks of ovarian failure related to the different chemotherapy protocols, then on the main pathophysiological mechanisms involved in ovarian toxicity.